Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Τίτλος | Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., Tikas I., Christodoulou C., Chatzopoulos K., Bobos M., Pentheroudakis G., Tsolaki E., Batistatou A., Kotsakis A., Koutras A., Linardou H., Razis E., Res E., Pectasides D., & Fountzilas G. |
Journal | Clin Breast Cancer |
Volume | 19 |
Issue | 2 |
Pagination | 113-125.e4 |
Date Published | 2019 04 |
ISSN | 1938-0666 |
Λέξεις κλειδιά | Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Breast Neoplasms, Chemotherapy, Adjuvant, Class I Phosphatidylinositol 3-Kinases, Female, Genotype, Humans, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Receptor, ErbB-2, Trastuzumab, Tumor Suppressor Protein p53 |
Abstract | BACKGROUND: We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent. |
DOI | 10.1016/j.clbc.2018.10.014 |
Alternate Journal | Clin. Breast Cancer |
PubMed ID | 30545790 |